PAREXEL International Corporation, a biopharmaceutical services company, has reported that net income for the third quarter ended March 31, 2013 was $29.52 million, or $0.50 per diluted share, compared to $22.87 million, or $0.38 per diluted share, for ...
[Published Individual.com - May 15 2013]